These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20080897)

  • 1. SUV: from silly useless value to smart uptake value.
    Visser EP; Boerman OC; Oyen WJ
    J Nucl Med; 2010 Feb; 51(2):173-5. PubMed ID: 20080897
    [No Abstract]   [Full Text] [Related]  

  • 2. SUV: standard uptake or silly useless value?
    Keyes JW
    J Nucl Med; 1995 Oct; 36(10):1836-9. PubMed ID: 7562051
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative assessment of methods for estimating tumor volume and standardized uptake value in (18)F-FDG PET.
    Tylski P; Stute S; Grotus N; Doyeux K; Hapdey S; Gardin I; Vanderlinden B; Buvat I
    J Nucl Med; 2010 Feb; 51(2):268-76. PubMed ID: 20080896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injected dose in pediatric PET.
    Watson CC
    J Nucl Med; 2010 Oct; 51(10):1657; author reply 1657-8. PubMed ID: 20847164
    [No Abstract]   [Full Text] [Related]  

  • 6. [PET?: comfortable whole body checkup].
    Hanafusa K
    Nihon Hoshasen Gijutsu Gakkai Zasshi; 2006 Jun; 62(6):781-5. PubMed ID: 16856256
    [No Abstract]   [Full Text] [Related]  

  • 7. [Monitorized use of 18FDG positron emission tomography].
    Rodríguez Garrido M; Asensio del Barrio C
    Rev Esp Med Nucl; 2006; 25(3):217-20. PubMed ID: 16871675
    [No Abstract]   [Full Text] [Related]  

  • 8. [18F]Fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy.
    De Giorgi U; Amadori D
    J Clin Oncol; 2010 May; 28(15):e236-7; author reply e238. PubMed ID: 20177016
    [No Abstract]   [Full Text] [Related]  

  • 9. Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose.
    Shiue CY; Welch MJ
    Radiol Clin North Am; 2004 Nov; 42(6):1033-53, viii. PubMed ID: 15488556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased glucose uptake by seborrheic keratosis detected by positron emission tomography.
    Ibusuki A; Higashi Y; Kanekura T
    J Dermatol; 2011 Jan; 38(1):104-5. PubMed ID: 21175767
    [No Abstract]   [Full Text] [Related]  

  • 11. [Usefulness of 18F-FDG-PET in breast cancer imaging].
    Tayama K; Toh U; Fujii T; Shirouzu K; Kaida Y
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():373-8. PubMed ID: 17679209
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center study.
    de Jong WK; van der Heijden HF; Pruim J; Dalesio O; Oyen WJ; Groen HJ
    J Thorac Oncol; 2007 Nov; 2(11):1007-12. PubMed ID: 17975491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined (18)F-FDG and fluoride approach in PET/CT imaging: is there a clinical future?
    Bailey DL
    J Nucl Med; 2010 Jan; 51(1):165-6; author reply 166-7. PubMed ID: 20008991
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential clinical utility of dual time point FDG-PET for distinguishing benign from malignant lesions: implications for oncological imaging.
    Sanz-Viedma S; Torigian DA; Parsons M; Basu S; Alavi A
    Rev Esp Med Nucl; 2009; 28(3):159-66. PubMed ID: 19558958
    [No Abstract]   [Full Text] [Related]  

  • 15. Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size.
    Nomori H; Watanabe K; Ohtsuka T; Naruke T; Suemasu K; Uno K
    Ann Thorac Surg; 2005 Mar; 79(3):984-8; discussion 989. PubMed ID: 15734419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Quality control of PET imaging: from study to diagnosis].
    Daisaki H
    Nihon Hoshasen Gijutsu Gakkai Zasshi; 2012; 68(7):916-25. PubMed ID: 22821167
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic value of the standardized uptake value in esophageal cancer.
    van Westreenen HL; Plukker JT; Cobben DC; Verhoogt CJ; Groen H; Jager PL
    AJR Am J Roentgenol; 2005 Aug; 185(2):436-40. PubMed ID: 16037517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined (18)F-FDG and fluoride approach in PET/CT imaging: is there a clinical future?
    Basu S; Rao R
    J Nucl Med; 2010 Jan; 51(1):165; author reply 166-7. PubMed ID: 20008984
    [No Abstract]   [Full Text] [Related]  

  • 19. Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography.
    Kato H; Fukuchi M; Miyazaki T; Nakajima M; Tanaka N; Inose T; Kimura H; Faried A; Saito K; Sohda M; Fukai Y; Masuda N; Manda R; Ojima H; Tsukada K; Oriuchi N; Endo K; Nonaka T; Shioya M; Ishikawa H; Sakurai H; Nakano T; Kuwano H
    Anticancer Res; 2007; 27(4C):2627-33. PubMed ID: 17695425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is FDG-PET indicated for superficial esophageal cancer?
    Little SG; Rice TW; Bybel B; Mason DP; Murthy SC; Falk GW; Rybicki LA; Blackstone EH
    Eur J Cardiothorac Surg; 2007 May; 31(5):791-6. PubMed ID: 17337344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.